Sequential to Host Inaugural London Summit on Ingredient Innovation

The one-day forum, titled The Future of Next-Generation Ingredients & Validation, focuses on the intersection of bioengineering and market-ready clinical evidence. Sequential CEO Dr. Oliver Worsley intends to bridge the gap between AI-driven discovery and the rigorous verification standards now expected by global consumers.

Sessions will cover a breadth of topics including longevity research, healthy aging protocols, and bioengineered ingredient discovery. The program features a roster of experts, including keynote speaker Lieve Declercq of Proya Companies, alongside specialists from dsm-firmenich, Medik8, and The Honey Pot Company. Dr. Amir Jassim and Albert Dashi, Sequential’s co-founder, will also present findings on the role of clinical biomarkers in accelerating research across skin, scalp, and oral care sectors.